Squarepoint
REGN icon

Squarepoint’s Regeneron Pharmaceuticals REGN Stock Holding History

Squarepoint’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.42M Sell
10,900
-17,100
-61% -$13.1M 0.01% 1165
2025
Q4 		$21.6M Buy
28,000
+2,000
+8% +$1.36M 0.02% 705
2025
Q3 		$14.6M Sell
26,000
-21,700
-45% -$12.3M 0.01% 902
2025
Q2 		$25M Buy
47,700
+20,800
+77% +$11.6M 0.03% 660
2025
Q1 		$17.1M Sell
26,900
-26,100
-49% -$18M 0.02% 764
2024
Q4 		$37.8M Buy
53,000
+37,400
+240% +$31.4M 0.04% 476
2024
Q3 		$16.4M Buy
15,600
+1,900
+14% +$2.11M 0.03% 687
2024
Q2 		$14.4M Sell
13,700
-5,700
-29% -$5.53M 0.02% 743
2024
Q1 		$18.7M Buy
19,400
+9,600
+98% +$9.13M 0.03% 647
2023
Q4 		$8.61M Sell
9,800
-11,200
-53% -$9.22M 0.02% 1036
2023
Q3 		$17.3M Sell
21,000
-300
-1% -$236K 0.04% 526
2023
Q2 		$15.3M Buy
21,300
+20,700
+3,450% +$16M 0.05% 487
2023
Q1 		$493K Sell
600
-4,400
-88% -$3.32M ﹤0.01% 2309
2022
Q4 		$3.61M Hold
5,000
– – 0.01% 1007
2022
Q3 		$3.44M Sell
5,000
-400
-7% -$252K 0.02% 972
2022
Q2 		$3.19M Buy
5,400
+300
+6% +$195K 0.02% 909
2022
Q1 		$3.56M Sell
5,100
-3,300
-39% -$2.09M 0.02% 857
2021
Q4 		$5.3M Buy
8,400
+500
+6% +$307K 0.01% 771
2021
Q3 		$4.78M Buy
7,900
+300
+4% +$186K 0.01% 795
2021
Q2 		$4.25M Sell
7,600
-8,600
-53% -$4.36M 0.02% 802
2021
Q1 		$7.67M Buy
16,200
+8,600
+113% +$4.19M 0.04% 456
2020
Q4 		$3.67M Buy
+7,600
New +$4.1M 0.03% 623

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Squarepoint's REGN Position: Q1 2026 in Review

Squarepoint increased its Regeneron Pharmaceuticals (REGN) stake by 5,962% in Q1 2026, buying an estimated $123M and bringing the position to 162,814 shares worth $126M. The position accounts for 0.15% of the portfolio, ranked #118.

Squarepoint first reported a position in REGN in Q1 2016 and has held it in 32 quarters since. The position peaked at $181M in Q4 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Squarepoint held 162,814 shares of Regeneron Pharmaceuticals worth $126M as of Q1 2026.
  • Squarepoint bought 160,128 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $123M.
  • Regeneron Pharmaceuticals made up 0.15% of Squarepoint's portfolio in Q1 2026, its #118 holding.
  • Squarepoint first reported a position in Regeneron Pharmaceuticals in Q1 2016 and has held it in 32 quarters since.
  • Squarepoint's Regeneron Pharmaceuticals position peaked at $181M in Q4 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.